Table 2.
Patient Baseline Characteristics and Response to Co-Treatment of nAMD by Intraocular Bevacizumab and Oral Doxycycline. Data are Means ± Standard Deviation unless Otherwise Stated
| Values | |
|---|---|
| Age, years | 75.5 ± 7.7 |
| Sex, female:male ratio, n (%) | 12 (54.5%):10 (45.5%) |
| Initial lesion size, disc diameter | 1.25 ± 0.65 |
| Initial visual acuity score * | 28.5 ± 22.57 |
| Initial thickness of the foveal central portion, m | 445.14 ± 63.69 |
| Visual acuity score change | 7.92 ± 16.89 (P = 0.03) |
| Foveal thickness change, m | 232.68 ± 69.25 (P < 0.001) |
| Final visual acuity score | 36.45 ± 26.66 |
| Final central foveal thickness, micrometer | 212.45 ± 29.50 |
| Number of consumed doxycycline tablets | 212.5 ± 7.5 |
| Total number of injections in 12 months | 3.18 ± 0.79 |
*
based on Early Treatment Diabetic Retinopathy Study (ETDRS) charts